OpenURL Connection Search

Select item for more details and to access through your institution.

A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial.
Published in:
Prostate, 1991, v. 18, n. 2, p. 139, doi. 10.1002/pros.2990180206
By:
- Citrin, Dennis L.;
- Resnick, Martin I.;
- Guinan, Patrick;
- Al-Bussam, Nazar;
- Scott, Mark;
- Gau, Timothy C.;
- Kennealey, Gerard T.
Publication type:
Article
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Published in:
Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 547, doi. 10.1007/s10549-018-4770-6
By:
- O’Shaughnessy, Joyce;
- DeMichele, Angela;
- Ma, Cynthia X.;
- Richards, Paul;
- Yardley, Denise A.;
- Wright, Gail Shaw;
- Kalinsky, Kevin;
- Steis, Ronald;
- Diab, Sami;
- Kennealey, Gerard;
- Geschwindt, Ryan;
- Jiang, Wei;
- Rugo, Hope S.
Publication type:
Article
Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
Published in:
1978
By:
- Kennealey, Gerard T.;
- Boston, Barry;
- Mitchell, Malcolm S.;
- Knobf, Mary Kathryn;
- Bobrow, Samuel N.;
- Pezzimenti, John F.;
- Lawrence, Roberta;
- Bertino, Joseph R.;
- Kennealey, G T;
- Boston, B;
- Mitchell, M S;
- Knobf, M K;
- Bobrow, S N;
- Pezzimenti, J F;
- Lawrence, R;
- Bertino, J R
Publication type:
journal article
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
Published in:
2018
By:
- Giaccone, Giuseppe;
- Sanborn, Rachel E.;
- Waqar, Saiama N.;
- Martinez-Marti, Alex;
- Ponce, Santiago;
- Huiling Zhen;
- Kennealey, Gerard;
- Erickson-Viitanen, Susan;
- Schaefer, Eric;
- Zhen, Huiling
Publication type:
journal article
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
Published in:
1993
By:
- Matzkin, Haim;
- Soloway, Mark S.;
- Schellhammer, Paul F.;
- Chodak, Gerald;
- Smith, Joseph A.;
- Caplan, Richard;
- Kennealey, Gerard T.;
- Matzkin, H;
- Soloway, M S;
- Schellhammer, P F;
- Chodak, G;
- Smith, J A;
- Caplan, R;
- Kennealey, G T
Publication type:
journal article

Found: 5

A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.